Wednesday, February 10, 2010, 12:41PM AEST - The Australian Stockmarket closes in 3 hours and 24 minutes.
To create a watchlist or portfolio of shares, Register

DUSA Pharmaceuticals Inc. (DUSA)

7:54AM AEST: 1.41 USD  Up 0.05 (3.68%)  
 MORE ON DUSA 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 DUSA Pharmaceuticals, Inc. (NGM:DUSA) Delayed quote dataEdit
Last Trade:1.41 USD
Trade Time: 7:54AM AEST
Change:Up 0.05 (3.68%)
Prev Close:1.36
Open:1.40
Bid:1.21 x 1500
Ask:1.49 x 3000
1y Target Est:6.00
Day's Range:1.37 - 1.44
52wk Range:0.88 - 1.87
Volume:56,060
Avg Vol (3m):82,360.3
Market Cap:33.99M
P/E (ttm):N/A
EPS (ttm):-0.20
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add DUSA to Portfolio   Download Data

 HEADLINES 
DUSA Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
PR Newswire (Wed, Feb 3)
DUSA PHARMACEUTICALS INC Financials
EDGAR Online Financials (Sat, Nov 14)
DUSA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Sat, Nov 7)
[video] The Pisani Paradox
at TheStreet.com (Tue, Sep 29)
DUSA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Wed, Aug 12)
DUSA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Wed, May 13)
DUSA Pharmaceuticals Reports First Quarter 2009 Corporate Highlights and Financial Results
Marketwire (Tue, May 12)
DUSA Initiates Clinical Trial of Levulan(R) PDT on High-Risk Solid Organ Transplant Recipients
Marketwire (Mon, May 11)
DUSA Pharmaceuticals, Inc. Announces First Quarter Financial Results and Corporate Highlights Conference Call
Marketwire (Thu, May 7)
DUSA Hits the Road With The Skin Cancer Foundation to Raise Awareness of Skin Cancer
Marketwire (Tue, May 5)
More Headlines for DUSA...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.13
EPS Est (in 2 years) (Dec-10) :0.03
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
DUSA Pharmaceuticals, Inc., an integrated dermatology pharmaceutical company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices